Last checked at 3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News7
GSK Share
Chat3
GSK Share
Trades10,225
GSK
Live RNS2
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings1
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,705.00
Bid:
1,701.00
Ask:
1,701.50
Change:
32.00 (1.91%)
Spread:
0.50 (0.029%)
Open:
1,685.50
High:
1,718.50
Low:
1,673.00
Prev. Close:
1,673.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Sector movers: GSK leads defensive pharma stocks higher
Wed, 04th Feb 2015 14:35
A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high.Sales, profits and earnings slumped during the fourth quarter of the year at GSK due to headwinds in the US market, though the company pleased investors after confirming it would return £4bn cash from its deal with Novartis.The company also posted a dividend of 80p, a rise of 3%, and said it expected to maintain it at the same level in 2015.Glaxosmithkline's shares were up 1.1% at 1,468.5p.Meanwhile, healthcare outsourcer Synergy Health was also advancing 0.7% after saying it was on track to hit full-year forecasts as growth momentum picked up strongly in the third quarter.Sector giant Astrazeneca also gained, along with Hikma Pharmaceuticals, Consort Medical and Skyepharma, as defensive sectors such as pharmaceuticals rose amid a wider market decline.Pharma stocks have underperformed over the last few sessions as strong gains on the back of easing concerns over Greece pushed risk assets such as miners and oil producers higher. The FTSE 100 reached its highest close since early-September 2014 on Tuesday.Top performing sectors so far todayPharmaceuticals & Biotechnology 13,488.72 +1.14%Technology Hardware & Equipment 1,245.55 +1.11%Software & Computer Services 1,305.71 +0.41%Construction & Materials 4,637.12 +0.26%Electronic & Electrical Equipment 3,990.66 +0.25%Bottom performing sectors so far todayOil Equipment, Services & Distribution 16,336.00 -3.09%Industrial Metals & Mining 1,669.36 -2.81%Oil & Gas Producers 7,313.61 -2.02%Mining 14,227.96 -1.75%Food Producers & Processors 8,069.40 -1.56%
More News
3 Jan 2024 08:58
LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.
Read more3 Jan 2024 07:54
LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data
(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.
Read more29 Dec 2023 13:01
LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023
(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.
Read more20 Dec 2023 13:29
GSK buys rights to Hansoh Pharma antibody-drug conjugate
(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.
Read more19 Dec 2023 15:36
German court quashes CureVac patent after challenge by BioNTech
CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue
*Read more18 Dec 2023 17:21
Energy stocks lift UK's FTSE 100, Vodafone shines
Vodafone jumps as Iliad offers to merge Italian units
*Read more18 Dec 2023 10:07
GSK's dostarlimab trial in endometrial cancer meets primary endpoint
(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.
Read more18 Dec 2023 07:55
LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000
(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.
Read more18 Dec 2023 07:18
GSK sees success in Jemperli endometrial cancer trial
(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.
Read more17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more